Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford,UK.
Rheumatology (Oxford). 2011 May;50(5):899-905. doi: 10.1093/rheumatology/keq400. Epub 2010 Dec 13.
Assessment of disease activity in vasculitis can be achieved using the BVAS, a clinical checklist of relevant symptoms, signs and features of active disease. The aim of this study was to revalidate the BVAS version 3 (BVAS v. 3) in a cohort of patients with systemic vasculitis.
A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single time point. Spearman's correlation coefficients were calculated between BVAS v. 3 scores, vasculitis activity index (VAI), physician's global assessment (PGA), the physician's treatment decision, CRP and the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity.
WG (63%), Churg-Strauss syndrome (9%) and microscopic polyangiitis (9%) were the most common diagnoses. The BVAS v. 3 showed convergent validity with the VAI [ρ = 0.82 (95% CI 0.77, 0.85)], PGA [ρ = 0.85 (95% CI 0.81, 0.88)] and the physician's treatment decision [ρ = 0.54 (95% CI 0.44, 0.62)]. There was little or no correlation between BVAS v. 3 and the CRP level [ρ = 0.18 (95% CI 0.05, 0.30)] or with the VDI [ρ = -0.10 (95% CI 0.22, 0.03)]. The inter-observer reliability was very high with an intra-class correlation coefficient (ICC) of 0.996 (95% CI 0.990, 0.998) for the total BVAS v. 3 score.
The BVAS v. 3 has been evaluated in a large cohort of patients with vasculitis and the important properties of the tool revalidated. This study increases the utility of the BVAS v. 3 in different populations of patients with systemic vasculitis.
使用 BVAS（一种有关疾病活动的临床检查表，其中包含相关症状、体征和疾病活动特征）可评估血管炎的疾病活动度。本研究的目的是在系统性血管炎患者队列中重新验证 BVAS 版本 3（BVAS v. 3）。
来自欧洲七个国家的 238 名血管炎患者在一个时间点接受评估。计算 BVAS v. 3 评分、血管炎活动指数（VAI）、医生整体评估（PGA）、医生治疗决策、CRP 和血管炎损伤指数（VDI）之间的 Spearman 相关系数，以证明 BVAS v. 3 可衡量疾病活动度。
WG（63%）、Churg-Strauss 综合征（9%）和显微镜下多血管炎（9%）是最常见的诊断。BVAS v. 3 与 VAI [ρ=0.82（95%CI 0.77，0.85）]、PGA [ρ=0.85（95%CI 0.81，0.88）] 和医生的治疗决策 [ρ=0.54（95%CI 0.44，0.62）] 具有一致性。BVAS v. 3 与 CRP 水平 [ρ=0.18（95%CI 0.05，0.30）] 或 VDI [ρ=-0.10（95%CI 0.22，0.03）] 之间几乎没有相关性。总 BVAS v. 3 评分的观察者间可靠性非常高，组内相关系数（ICC）为 0.996（95%CI 0.990，0.998）。
BVAS v. 3 已在大量血管炎患者中进行了评估，并重新验证了该工具的重要特性。本研究增加了 BVAS v. 3 在不同人群中评估系统性血管炎的实用性。
